The analysis revealed a landscape of CAFs in pancreatic cancer during in vivo tumor development. The LRRC15+ CAF lineage was shown to be TGFβ-dependent and correlated with a poor patient outcome treated with immunotherapy in multiple solid tumor entities. This evidence concerns the gene TGFB1 and neoplasm.